Mark Giganti

Biography

Education and Training

• MS, Biostatistics
  University of Washington
• PhD, Biostatistics
  Vanderbilt University
• BS, Statistics, Mathematics
  University of Missouri

Publications

• Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial.

  Giganti MJ, Chew KW, Moser C, Eron JJ, Pinilla M, Li JZ, Ritz J, Javan AC, Wohl DA, Daar ES, Currier JS, Smith DM, Hughes MD. Contemp Clin Trials 2025

  PMID: 40147543

• Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies.

  Bender Ignacio RA, Chew KW, Moser C, Currier JS, Eron JJ, Javan AC, Giganti MJ, Ritz J, Gibbs M, Kouekam HT, Esser MT, Daar ES, Choudhary M, Deo R, Fletcher CV, Li JZ, Hughes MD, Smith D, Wohl DA. iScience 2025 Mar 21

  PMID: 40124489

• Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial.

  Chew KW, Taiwo BO, Moser C, Daar ES, Wohl DA, Ritz J, Javan AC, Li JZ, Fischer W, Greninger AL, Bausch C, Luke T, Call R, Neytman G, Giganti MJ, Fletcher CV, Hughes MD, Eron JJ, Currier JS, Smith DM. J Infect Dis 2024 Nov 15

  PMID: 39028902

• Infectivity and Immunogenicity of Live-Attenuated Respiratory Syncytial Virus Vaccines in Human Immunodeficiency Virus-Exposed Uninfected Children.

  Kelly MS, Cunningham CK, McFarland EJ, Giganti MJ, Lindsey JC, Perlowski C, Libous JL, Jean-Philippe P, Moye J, Karron RA, Collins PL, Buchholz UJ. Open Forum Infect Dis 2024

  PMID: 39610407

• SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19.

  Jilg N, Giganti MJ, Chew KW, Shaw-Saliba K, Ritz J, Moser C, Evering TH, Daar ES, Eron JJ, Currier JS, Hughes MD, Lane HC, Dewar R, Smith DM, Li JZ. Clin Infect Dis 2024 10 15

  PMID: 39018444